Similar articles

• [Statin cuts cardiovascular risk in half].

  Einecke D. Einecke D. MMW Fortschr Med. 2008 Dec 4;150(49-50):12-3. MMW Fortschr Med. 2008. PMID: 19133364 German. No abstract available.
• The numbers are in: statins for the primary prevention of cardiovascular disease in women.

  Duvernoy CS, Blumenthal R. Duvernoy CS, et al. Circulation. 2010 Mar 9;121(9):1063-5. doi: 10.1161/CIR.0b013e3181d731c6. Epub 2010 Feb 22. Circulation. 2010. PMID: 20176993 No abstract available.
• JUPITER study highlights value of anti-inflammatory action of rosuvastatin.

  [No authors listed] [No authors listed] Cardiovasc J Afr. 2009 May-Jun;20(3):211. Cardiovasc J Afr. 2009. PMID: 19575096 No abstract available.
• Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

  Ridker PM; JUPITER Study Group. Ridker PM, et al. Circulation. 2003 Nov 11;108(19):2292-7. doi: 10.1161/01.CIR.0000100688.17280.E6. Circulation. 2003. PMID: 14609996 Review. No abstract available.
• Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?

  Mora S, Ridker PM. Mora S, et al. Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1. Am J Cardiol. 2006. PMID: 16442935 Review.